Showing 4721-4730 of 6036 results for "".
- Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022https://modernod.com/news/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-at-angiogenesis-2022/2480640/Opthea announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,&r
- Novartis Presents Positive Results From Three Phase 3 Trials of Beovu in DMEhttps://modernod.com/news/novartis-presented-positive-results-from-three-phase-3-trials-of-beovu-in-dme/2480638/At the Angiogenesis, Exudation, and Degeneration 2022 Virtual Meeting, Novartis presented additional positive results from three phase 3 trials of Beovu in DME, including results from patients dosed at up to 16-week intervals. This was the first detailed presentation of the year 2 results&nb
- Regeneron Presents Encouraging Phase 2 Results for High-Dose Aflibercept 8 mg in Wet AMDhttps://modernod.com/news/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-amd/2480636/Regeneron Pharmaceuticals announced results from its phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (AMD). The resul
- Waldo Announces the Acquisition of Placid0, Maker of Eye Assessment Apphttps://modernod.com/news/waldo-announces-the-acquisition-of-placid0/2480632/Waldo announces the acquisition of Placid0, maker of EASY, an eye assessment system mobile application. Financial terms of the deal were not disclosed. The acquisition is the next step in Waldo’s movement to make eye care an essential part of everyday life, with bo
- New 2-Year Data for Genentech’s Vabysmo and Susvimo Show Potential of Fewer Treatments for People With Wet AMD and DMEhttps://modernod.com/news/new-2-year-data-for-genentechs-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-wet-amd-and-dme/2480631/Genentech announced that new 2-year data from its phase 3 studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022 on February 12. These longer-term r
- Bausch Health Files for Solta IPOhttps://modernod.com/news/bausch-health-files-for-solta-ipo/2480629/Bausch Health Companies announced today that its wholly owned subsidiary, Solta Medical Corporation, has publicly filed for a proposed initial public offering (IPO). Solta, a provider of dermatology-focused lasers, has applied to list its common shares on the Nasdaq Global Select M
- Quantel Medical Launches C.STIM, a New Generation IPL System for Dry Eyehttps://modernod.com/news/quantel-medical-launches-a-new-generation-ipl-system-cstim/2480625/Quantel Medical announced the launch of C.STIM IPL system. Based on intense pulsed light technology, C.STIM is the new generation of IPL designed to treat the root causes of dry eyes: meibomian gland dysfunction, inflammation, and demodex. “Thanks to the unique
- Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operationshttps://modernod.com/news/outlook-therapeutics-expands-commercial-team-with-appointment-of-senior-vice-president-of-commercial-operations/2480623/Outlook Therapeutics, which is working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.
- Eyenovia Concludes Type A Meeting with FDA Related to MydCombi NDA Resubmissionhttps://modernod.com/news/eyenovia-concludes-type-a-meeting-with-fda-related-to-mydcombi-nda-resubmission/2480621/Eyenovia announced that the company successfully completed a meeting with the FDA related to the refiling of the NDA for MydCombi. On October 22, 2021, Eyenovia received a complete response letter (CRL) from the FDA stating that MydCombi, the co
- Eyenovia Announces Changes to Board of Directorshttps://modernod.com/news/eyenovia-announces-changes-to-board-of-directors/2480618/Eyenovia announced changes to its Board of Directors. Sean Ianchulev, MD, PhD, Director, Chief Executive Officer and Chief Medical Officer of Eyenovia, has been appointed Chairman Kenneth Lee, Jr., Director, has been named Lead Director